Literature DB >> 20439670

Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor.

Amalia M DeComas1, Patrice Penfornis, Michael R Harris, Mark S Meyer, Radhika R Pochampally.   

Abstract

BACKGROUND: Extra-axial chordomas are rare low-grade malignant tumors thought to arise from notochordal remnants in the extra-axial skeleton. Few studies have been done on this neoplasm because of its rarity. In addition, there is a lack of a good in vitro model on which to perform more characterization.
METHODS: We describe a twenty-eight-year-old man with a mass in the right scapula. Cytomorphology and immunohistochemistry, including brachyury staining, were used to formulate the final diagnosis. A fragment of the tumor was placed in culture, and cells obtained were injected subcutaneously in an immunocompromised mouse. From the tumor developed in mice, a cell line has been derived and characterized by fluorescence-activated cell-sorting analysis, karyotyping, clonogenicity, and cell and tumor growth curves.
RESULTS: Cytomorphology on the tumor showed nests of round cells with vacuoles and also physaliferous-like cells with uniform nuclei. Immunochemistry revealed a tumor positive for vimentin, moderately positive for S-100 and cytokeratin AE1/AE3, weakly positive for epithelial membrane antigen, and negative for p63 and cytokeratin (CK)-7. Further analysis revealed the tumor was diffusely and strongly positive for brachyury. The cell line derived from the tumor showed rapid doubling-time, a strong expression of mesenchymal cell surface markers, a karyotype of diploid or hypotetraploid clones with numerous chromosomal aberrations, and the ability to form colonies without attachment and to form tumors in immunocompromised mice.
CONCLUSIONS: The diagnosis of the extra-axial chordoma is difficult but can be resolved by the detection of a strong brachyury expression. In addition, the derivation of a human extra-axial chordoma cell line could be a useful tool for the basic research of this rare neoplasm.

Entities:  

Mesh:

Year:  2010        PMID: 20439670      PMCID: PMC7000130          DOI: 10.2106/JBJS.I.00594

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  26 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

2.  Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation.

Authors:  Paul O'donnell; Roberto Tirabosco; Sonja Vujovic; William Bartlett; Timothy W R Briggs; Stephen Henderson; Chris Boshoff; Adrienne M Flanagan
Journal:  Skeletal Radiol       Date:  2006-06-30       Impact factor: 2.199

3.  Extra-axial chordoma.

Authors:  Lisa M DiFrancesco; Cristobal A Davanzo Castillo; Walley J Temple
Journal:  Arch Pathol Lab Med       Date:  2006-12       Impact factor: 5.534

Review 4.  Cancer: the evolved consequence of a destabilized genome.

Authors:  G R Anderson; D L Stoler; B M Brenner
Journal:  Bioessays       Date:  2001-11       Impact factor: 4.345

5.  Brachyury and chordoma: the chondroid-chordoid dilemma resolved?

Authors:  S Romeo; P C W Hogendoorn
Journal:  J Pathol       Date:  2006-06       Impact factor: 7.996

6.  Parachordoma is immunohistochemically and cytogenetically distinct from axial chordoma and extraskeletal myxoid chondrosarcoma.

Authors:  A L Folpe; S N Agoff; J Willis; S W Weiss
Journal:  Am J Surg Pathol       Date:  1999-09       Impact factor: 6.394

7.  Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis.

Authors:  Gerard J Oakley; Kim Fuhrer; Raja R Seethala
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

8.  Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients.

Authors:  J Bjornsson; L E Wold; M J Ebersold; E R Laws
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

9.  Differential diagnosis of chordoma, chondroid, and ependymal tumors as aided by anti-intermediate filament antibodies.

Authors:  M Miettinen; V P Lehto; D Dahl; I Virtanen
Journal:  Am J Pathol       Date:  1983-08       Impact factor: 4.307

10.  Extra-axial chordoma presenting as a lung mass.

Authors:  Seung Yong Park; So Ri Kim; Yeong Hun Choe; Ka Young Lee; Seoung Ju Park; Heung Bum Lee; Gong Yong Jin; Kyu Yun Jang; Yong Chul Lee
Journal:  Respiration       Date:  2008-05-22       Impact factor: 3.580

View more
  12 in total

1.  Establishment and characterization of a primary human chordoma xenograft model.

Authors:  I-Mei Siu; Vafi Salmasi; Brent A Orr; Qi Zhao; Zev A Binder; Christine Tran; Masaru Ishii; Gregory J Riggins; Christine L Hann; Gary L Gallia
Journal:  J Neurosurg       Date:  2012-01-27       Impact factor: 5.115

Review 2.  Intra-articular extra-axial chordoma of the wrist: a case report with review of the current literature.

Authors:  Jan Neumann; Alexandra S Gersing; Thomas F Barth; Melanie Boxberg; Klaus Woertler
Journal:  Skeletal Radiol       Date:  2019-05-18       Impact factor: 2.199

3.  Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Authors:  Wesley Hsu; Ahmed Mohyeldin; Sagar R Shah; Colette M ap Rhys; Lakesha F Johnson; Neda I Sedora-Roman; Thomas A Kosztowski; Ola A Awad; Edward F McCarthy; David M Loeb; Jean-Paul Wolinsky; Ziya L Gokaslan; Alfredo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2011-06-24       Impact factor: 5.115

4.  Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis.

Authors:  Xiaoyun Wen; Robert Cimera; Ruth Aryeequaye; Mohanty Abhinta; Edward Athanasian; John Healey; Nicola Fabbri; Patrick Boland; Yanming Zhang; Meera Hameed
Journal:  Genes Chromosomes Cancer       Date:  2021-08-26       Impact factor: 5.006

5.  Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.

Authors:  Jason M Davies; Aaron E Robinson; Cynthia Cowdrey; Praveen V Mummaneni; Gregory S Ducker; Kevan M Shokat; Andrew Bollen; Byron Hann; Joanna J Phillips
Journal:  J Neurosurg       Date:  2013-11-29       Impact factor: 5.115

6.  Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.

Authors:  Lucia Ricci-Vitiani; Daniele Runci; Quintino Giorgio D'Alessandris; Tonia Cenci; Maurizio Martini; Federico Bianchi; Giulio Maira; Louis Stancato; Ruggero De Maria; Luigi Maria Larocca; Roberto Pallini
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

Review 7.  Parosteal extra-axial chordoma of the second metacarpal bone: a case report with literature review.

Authors:  Shinji Tsukamoto; Daniel Vanel; Alberto Righi; Davide Maria Donati; Costantino Errani
Journal:  Skeletal Radiol       Date:  2017-11-18       Impact factor: 2.199

8.  Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma.

Authors:  Santosh S Dhule; Patrice Penfornis; Trivia Frazier; Ryan Walker; Joshua Feldman; Grace Tan; Jibao He; Alina Alb; Vijay John; Radhika Pochampally
Journal:  Nanomedicine       Date:  2011-08-10       Impact factor: 5.307

9.  Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets.

Authors:  Salvatore Di Maio; Esther Kong; Stephen Yip; Robert Rostomily
Journal:  Surg Neurol Int       Date:  2013-06-01

Review 10.  From notochord formation to hereditary chordoma: the many roles of Brachyury.

Authors:  Yutaka Nibu; Diana S José-Edwards; Anna Di Gregorio
Journal:  Biomed Res Int       Date:  2013-03-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.